References: 1. Simonneau G, Gatzoulis
MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25)(suppl D):D34-D41. 2. Pulmonary Hypertension Association. Scleroderma and Pulmonary
Hypertension.
https://phassociation.org/patients/aboutph/diseases-and-conditions-associated-with-ph/scleroderma.
Accessed November 27, 2017. 3. Scleroderma Foundation. Pulmonary Hypertension in Scleroderma. Danvers, MA: Scleroderma
Foudation; 2017. 4. Galie N, Eur Heart J. European Heart Journal. 2016;37(67-119). 5. McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. Pulmonary
arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009;48(Suppl 3):iii25-31. 6. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert
consensus document on pulmonary hypertension. Circulation.
2009;119(16):2250-2294.